Table 2: Proportion of amplified cells with MYCN amplification in every patient. MYCN amplification was quantified in every cell as significant, discreet and without amplification (the percentage given without the brackets is the number of analysed cells in the bone marrow, while the number given in the brackets represents proportion of cells in the tumor tissue).
|
Presence of amplification |
|
|
Patient 1 |
Patient 2 |
Patient 3 |
Patient 4 |
Patient 5 |
|||
|
before therapy |
after 6 months |
before therapy |
after 6 months |
before therapy |
after 6 months |
|||||
|
A. No MYCN amplification |
|
|
13% (9%) |
15% |
17% (36%) |
21% |
83% (77%) |
97% |
(80%) |
100% (100%) |
|
B.MYCN gain |
|
|
/ |
|
/ (10%) |
5% |
7% (11%) |
3% |
(20% ) 3 copies (trisomy 2) |
/ |
|
C.MYCN amplification |
C1. discrete |
|
22% (28%) |
28% |
11% (28%) |
9% |
6% (7%) |
/ |
/ |
/ |
|
C2.significant |
2a |
60% (51%) |
45% |
59% (20%) |
42% |
4% (5%) |
/ |
/ |
/ |
|
|
2b |
5% (12%) |
12% |
13% (6%) |
23% |
0% (0%) |
/ |
||||